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523Letters to the Editor 
Sir,
Cytomegalovirus (CMV) is a herpes virus with life-long 
persistence following primary infection. Forty percent 
of the population carry the virus by the age of 20 years 
and sixty percent by the age of 60 years. CMV infections 
are usually asymptomatic, but in the immuno-compro-
mised patient reactivation or a primary infection may 
cause severe disease, with retinitis, colitis, hepatitis or 
pneumonia. 
TNF-α mediates host-resistance against micro-
organisms and inhibits CMV replication and serum 
TNF-α is elevated during acute CMV-infections (1). 
TNF-α blocking agents (infliximab, etanercept and 
adalimumab) block the pivotal role of TNF-α in the 
inflammatory response. Efalizumab is a monoclonal 
antibody directed against the CD11a subunit of LFA 1 
on lymphocytes, thereby blocking lymphocyte to 
antigen-presenting cells interaction and diapedesis. 
We describe here 2 cases of CMV infection in patients 
receiving biological treatment. 
CASE REPORTS
Case 1
A 37-year-old man with psoriasis since the age of 16 
years and psoriatic arthritis since the age of 36 years 
was treated with etanercept 50 mg twice weekly with 
excellent clinical response. 
After one month of treatment, fever and ear pains 
raised the suspicion of otitis media in the patient; 
he was treated with penicillin and recovered. Two 
months later he developed fever, productive cough 
and malaise. Pneumonia was suspected and eternacept 
treatment was stopped. Biochemical analysis showed 
no signs of infection and chest X-ray was normal. His 
symptoms were persistent and he was admitted to hos-
pital with fever of unknown origin (FUO). He was fati-
gued and confined to bed. Biochemistry: liver function 
tests (LFT) were raised with alanin-aminotransferase 
135 U/l (10–70), aspartat-aminotransferase 167 U/l 
(15–45), gamma-glutamyltransferase 196 U/l (10–80) 
and alkaline phosphatase 143 U/l (35–105). Serum-
screening for a large array of infections was positive 
for IgM anti-CMV and negative for IgG anti-CMV. One 
month later he became CMV-IgG positive, indicating 
a primary infection with sero-conversion. CMV-PCR 
was not analysed initially, but it was later found to be 
negative. He received no antiviral treatment and reco-
vered slowly. He was restarted on eternacept 6 months 
later without CMV reactivation.
Case 2
A 59-year-old woman had had psoriasis and psoriatic 
arthritis since adolescence. She had side-effects to 
methotrexate and now received low-dose acitretin. This 
was supplemented with etanercept 50 mg twice weekly. 
After 6 months she was switched to efalizumab 100 mg 
weekly due to lack of efficacy of etanercept treatment. 
After 2 months she developed diarrhoea, malaise, 
weight-loss, anaemia and persistent lymphocytosis. 
LFT were unaffected. Efalizumab was halted. Serum 
screening for a large array of infections were positive 
for IgG and IgM anti-CMV, indicating either a reactiva-
tion or a primary infection in a late phase. She received 
no antiviral treatment, because the CMV infection was 
detected at a late stage. She slowly recovered to her 
usual condition over a 2–3-month period.
DISCUSSIOn
In any patient receiving biological therapy it is im-
portant to be aware of infections, because there is a risk 
of a long and aggressive course. The 2 patients described 
here, who were treated with etanercept and efalizumab, 
respectively, both had a longstanding infection.
CMV retinitis has been described in a female patient 
with rheumatoid arthritis treated with infliximab, Imurel 
(azathioprine) and cyclophosphamide. An additive ag-
gravating effect of the combined immuno-suppressive 
regimen cannot be excluded (1). Torre-Cisneros et al. (2) 
prospectively (week 0–6 of treatment) followed 15 patients 
with rheumatoid arthritis treated with infliximab (3 mg/kg) 
for reactivation of CMV, Epstein-Barr virus (EBV) and 
human herpes virus (HHV) 6, 7, and 8. No signs of re-
activation and no primary infections were detected.
It is well known from patients with AIDS, that im-
munosuppression may cause reactivation of CMV and 
increased susceptibility to primary infections, with poten-
tially debilitating out-comes (e.g. CMV retinitis) (3). 
In conclusion, TNF-α blocking agents and perhaps 
efalizumab may reactivate CMV or make the patient 
more susceptible to a primary infection. Our patients did 
not show asymptomatic infections, but were severely 
and prolonged fatigued. 
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Therefore in patients receiving biological treatment, 
who develop FUO, CMV should be considered. CMV 
may be identified immediately after infection or reac-
tivation by PCR-analysis, but repeated analyses of 
antibodies against CMV are often necessary.
Our patients recovered without antiviral therapy in 
approximately 2 months, but treatment should be con-
sidered in each case.
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